Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 3/20 | 0.42 |
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL402975 | 0.88 | KLK7 (0.44) | KLK7KLK5BCHEL3MBTL1SMN1; SMN2 | |
| SCHEMBL402461 | 0.86 | KLK7 (0.41) | KLK7KLK5BCHEL3MBTL1SMN1; SMN2 | |
| SCHEMBL402695 | 0.84 | ALDH1A1 (0.46) | KLK7KLK5ALDH1A1BCHEL3MBTL1 | |
| SCHEMBL19976411 | 0.83 | BCHE (0.46) | KLK7KLK5ALDH1A1BCHELMNA | |
| SCHEMBL402948 | 0.82 | ALDH1A1 (0.41) | ALDH1A1BCHEKMT2AMGLL | |
| SCHEMBL14363003 | 0.79 | LMNA (0.45) | KLK7KLK5ALDH1A1BCHEL3MBTL1 | |
| SCHEMBL24777143 | 0.79 | CA12 (0.38) | ALDH1A1BCHELMNAKMT2ANPSR1 | |
| SCHEMBL24943597 | 0.79 | CA12 (0.38) | ALDH1A1BCHELMNAKMT2ANPSR1 | |
| SCHEMBL14362885 | 0.78 | ALDH1A1 (0.39) | KLK7KLK5ALDH1A1BCHEMGLL | |
| SCHEMBL404432 | 0.77 | LMNA (0.44) | KLK7KLK5ALDH1A1BCHEL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065153-A1 | AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF | SANOFI-AVENTIS (FR) | 2012-03-15 | — | — | US | disclosed |
| US-20070270354-A1 | Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof | SANOFI-AVENTIS (FR) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065153-A1 | AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF | HPSE, HAAO, HEXD | KLK7 1399/4885KLK5 1277/4885ALDH1A1 371/4885 |
| US-20070270354-A1 | Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof | HPSE, HAAO, HEXD | KLK7 1402/4885KLK5 1250/4885ALDH1A1 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.